Table 1.
Demographic, clinical history, and baseline data for the randomized participants
| ID | Sex | Age of diagnosis | Disease duration | key medical, surgery, progression history | Current medications |
|---|---|---|---|---|---|
| 001 | M | 37 y | 19 y | Pallidotomy at 46 y Wheelchair use at 62 y PEG at 63 y |
DA drugs: Parcopa Non-DA drugs: rivastigmine transdermal |
| 003 | M | 60 y | 18 y | PD at 60 y STN-DBS at 70 y Walker/wheelchair at 77 y |
DA drugs: Sinemet R & CR Non-DA drugs: vitamin B12 |
| 004 | F | 56 y | 15 y | STN-DBS at 62 y Walker use at 68 y Wheelchair use at 70 y |
DA drugs: Sinemet R & CR, Rytary, Zelapar, Mirapex Non DA Drugs: dexlansoprazole, melatonin, midodrine, donepezil, memantine, clozapine, rimantadine, methylphenidate, venlafaxine fludrocortisdone |
| 006 | F | 58 y | 19 y | Walker use at 76 y Wheelchair at 77 |
DA drugs: Rytary, Sinemet Non-DA drugs: gabapentin, donepezil, lorazepam, quetiapine, melatonin, tramadol |
| 007 | M | 53 y | 23 y | Cane use at 73 y Wheelchair use at 75 y |
DA drugs: Rytary, rasagiline Non-DA drugs: donepezil |
| 008 | M | 42 y | 31 y | On L-dopa until 70 y Bed-bound at 70 y |
DA drugs: none* Non-DA drugs: none |
*:
L-dopa discontinued due to severe drowsiness.
Abbreviations:F: Female; M: Male; Y: years; STN: Subthalamic nucleus; DBS: Deep brain stimulation; PEG: Percutaneous endoscopic gastrostomy; DA: Dopaminergic; Sinemet: carbidopa/levodopa; R: regular release; CR: controlled release.